secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0000950170-23-004373
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma amends bylaws to align with SEC universal proxy rules and DGCL changes
--------------------------------------------------------------------------------

- Revised advance notice provisions requiring additional disclosures from proposing stockholders and nominees.
- Added requirement that stockholders using universal proxy rules certify compliance and provide evidence at least 5 business days before meeting.
- Updated adjournment procedures and list of stockholders to conform to recent DGCL amendments.
- Added emergency bylaw provision for director and officer authority during emergencies.
- Incorporated ministerial, clarifying, and conforming changes to align with DGCL and universal proxy rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023004373/0000950170-23-004373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023004373/stro-20230224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer